SNPs Pink Slips at DNA Sciences


DNA Sciences’ recent staff changes suggest a directional shift from traditional genomics to developing and commercializing diagnostic and drug-discovery products. The company fired chairman and CEO Hugh Reinhoff, whose position was assumed by former chief business officer Steve Lehrer. Suffering from what observers noted as a high cash burn rate, the company will also lay off roughly half of its 175-member workforce, according to a spokeswoman, who adds that most of the personnel cuts would be at the Fremont, Calif., headquarters.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.